BRINGING an ORPHAN DRUG to MARKET?

Rare disease programs cannot afford statistical missteps.
If you need experienced biostatistical leadership that understands small populations, adaptive methods, and regulatory expectations, let’s connect.

Orphan programs require a fundamentally different statistical framework.
Nooscend provides senior-level biostatistics leadership specialized in:
• Small population statistics
• Adaptive designs
• Bayesian modeling
• Natural history data integration
• CDISC submission packages
Built for regulatory submission to:
U.S. Food and Drug Administration
European Medicines Agency
Health Canada
If you’re advancing an orphan therapy, let’s build it right — from the start.